Institut National De La Sante Et De La Recherche Medicale

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Centre National De La Recherche Scientifique

Universitè De Montpellier

Université´ D'aix-Marseille

Institut Regional Du Cancer De Montpellier-Val D'aurelle

Institut Paoli Calmettes

Centre National De La Recherche Scientifique-Cnrs

Inserm

Jean-luc Teillaud

Christophe De Romeuf

Daniel Baty

Christine Gaucher

Isabelle Teulon

Jean-François Prost

Ghislaine Behar

Emmanuel Nony

Nicolas Bihoreau

Dominique Bourel

Wolf Herman Fridman

Andre Pelegrin

André Pelegrin

Martine Mansais

Martine Chartier

Sophie Siberil

The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.

Production of antibody formats and immunological applications of said formats

The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.

Antibody method for treatment of a disease in which the target cells are cells which express CD20

The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of Fc&#x3b3;RIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.

Monoclonal antibody directed against CD20 antigen

The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.

The present invention relates to a method for the production and the selection of human or chim&#xe6;ric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).

Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors

Growing community of inventors

Paris, France

Jean-luc Teillaud